Drugs / Compound Sodium Alginate Double Action Chewable Tablets
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01869491 Comparator | Jun 2013 → May 2014 | dyspepsia, gastroesophageal reflux disease | Reckitt Benckiser Healthcare (UK) Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Compound Sodium Alginate Double Action Chewable Tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01869491 ↗ |
| Known as | Gaviscon Double Action | “Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in...” PMID 26228097 ↗ Jul 2015 |
| Modality | Other / unclassified | “an alginate-antacid (Gaviscon Double Action) versus placebo” PMID 26228097 ↗ Jul 2015 |